Clinical trials: Precision Treatment
Solid Tumor, Gastric Cancer
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors
This study was planned as an open-label, multi-site, Phase I/IIa dose escalation, safety, and pharmacokinetic (PK) trial of BNT141 followed by expansion cohorts in patients with Claudin 18.2 (CLDN18.2)-positive tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04683939
- Testing
- BNT141, Nab-paclitaxel, Gemcitabine
- Where
- 7 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- BioNTech SE
Parkinson's Disease
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive…
- Trial name
- THOR201 (NCT03541356)
- Testing
- L-dopa 35 mg, L-dopa 70mg, L-dopa 140 mg
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Impel Pharmaceuticals
Chronic Pain
Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain
The primary objective of this study is to investigate patient satisfaction with treatment using a new implantable neurostimulation system for chronic pain of the trunk and/or limbs.
- Trial name
- NCT01665040
- Testing
- Neurostimulation device implantation
- Where
- 7 sites in Australia, Belgium and 1 more
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
Solid Tumour
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
This is a multi-center, open-label Phase 0 Master Protocol in Australia designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumour microenvironment (TME) when administered intratumourally in…
- Trial name
- NCT04891718
- Testing
- MVC-101, Nivolumab, MVC-101 + Nivolumab
- Where
- 3 sites in Australia
- Sponsor
- Presage Biosciences
Bipolar Disorder
Utility of the Pharmacogenetic Information Provided by NEUROPHARMAGEN in the Treatment of Bipolar Depressionwith Bipolar Depression
Evaluation of the impact of the genetic variation of individual genes on the therapeutic response and side effects profile in a cohort of well-characterized patients with bipolar depression, using NEUROPHARMAGEN.
- Trial name
- NCT04923204
- Testing
- Pharmacogenomic-testing with NEUROPHARMAGEN
- Where
- Spain
- Volunteers
- 76 people
- Sponsor
- AB Biotics, SA
Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome
The Precision Mito- Mito Map COMPASS Study
Mito Map is a research tool that produces an Energy Score from information provided by a participant. This remote observational study has an initial enrollment target of 400 adults across seven prespecified cohorts: healthy…
- Conditions
- Mitochondrial Diseases, Myalgic Encephalomyelitis Chronic Fatigue Syndrome, Post-COVID-19 Condition, Postural Orthostatic Tachycardia Syndrome
- Trial name
- COMPASS (NCT07856121)
- Testing
- Mito Map Energy Score and Home Functional Assessments
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- AI Agent Vault, Inc. d/b/a Precision Mito
Hypertension
H-Type Hypertension Precision Medicine Trial
This is a multicenter, randomized, double-blind, controlled clinical trial. It aims to investigate the effects of different doses of folic acid on lowering homocysteine (Hcy) in patients with hypertension with different genotypes…
- Trial name
- NCT03472508
- Testing
- Folic Acid, Enalapril Maleate and Folic Acid Tablets (Yiye), Enalapril
- Where
- 5 sites in China
- Volunteers
- 3,600 people
- Sponsor
- Shenzhen Ausa Pharmed Co.,Ltd
Chronic Pain
VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation
The primary objective of this study is to characterize the real-world outcomes of spinal cord stimulation (SCS) therapy as an aid in the management of chronic intractable pain of the trunk, including unilateral or bilateral pain…
- Trial name
- NCT02741297
- Testing
- Spinal Cord Stimulation (SCS) System
- Where
- 5 sites in Germany, Italy and 2 more
- Volunteers
- 73 people
- Sponsor
- Boston Scientific Corporation
Bipolar Disorder (BD), Schizophrenia Disorders
Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized Treatment for People With Serious Mental Illness
This observational study aims to provide new insights into the nature and classification of severe mental illness and dementias that in time should help improve diagnostic practise, and enable the development of new and improved…
- Conditions
- Bipolar Disorder (BD), Schizophrenia Disorders, Major Depressive Diorder, Dementia
- Trial name
- GlobalMinds (NCT06641726)
- Testing
- Not applicable- observational study
- Where
- United Kingdom
- Volunteers
- 50,000 people
- Sponsor
- Akrivia Health
Advanced Solid Tumor, Non-Small Cell Lung Cancer
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
A first in human study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BLU-924 / SAR449336, a pan-KRAS inhibitor, in participants with advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or…
- Conditions
- Advanced Solid Tumor, Non-Small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07629960
- Testing
- BLU-924
- Where
- 16 sites in United States, Spain
- Volunteers
- 265 people
- Sponsor
- Blueprint Medicines Corporation
Head and Neck Squamous Cell Carcinoma
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
This is a multi-center, open-label, Phase 0 substudy designed to evaluate the localized pharmacodynamics (PD) of rilvegostomig, volrustomig, sabestomig, and AZD9592 within the tumor microenvironment (TME) when administered…
- Trial name
- NCT06366451
- Testing
- Rilvegostomig, Volrustomig, Sabestomig
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Presage Biosciences